Health
Chronicle Pharmabiz
NPPA fixes retail price of 37 new drugs
THe National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of 37 new drugs in its recent meeting, under the provisions of the Drugs Prices Control Order (DPCO), 2013, including hypertensive medicines, anti-diabetic medicines, among others.
1 min |
January 1, 2026
Chronicle Pharmabiz
85% of overcharged amount claimed by NPPA yet to be recovered
INDIA's drug price monitoring and enforcing authority, the National Pharmaceutical Pricing Authority (NPPA), has almost 85% of the amount it demanded from the pharma industry on alleged overcharging of drug prices remaining pending for recovery till September 30, 2025, owing to various reasons including companies challenging the claim in the Court of Law.
1 min |
January 1, 2026
Chronicle Pharmabiz
Indian healthcare sector fuels rapid technology expansion
INDIAN healthcare sector has an influx of private capital alongside rapid technological acceleration, which is enabling a robust growth outlook.
2 min |
January 1, 2026
Chronicle Pharmabiz
Circadian rhythm regulation in delayed sleep phase syndrome
DELAYED Sleep phase syndrome (DSPS) is a most prevalent circadian rhythm sleep disorder and is marked by a delay in the timing of sleep episode compared to desired or necessary sleeping and wakeup times.
5 min |
January 1, 2026
Chronicle Pharmabiz
Odisha govt begins groundwork on ₹7,043 cr pharma commitments
AFTER the successful conclusion of the firstever Odisha Pharma Summit, the state government has moved into high gear to translate Rs. 7,043 crore in investment commitments into operational reality.
1 min |
January 1, 2026
Chronicle Pharmabiz
Heavens Will Not Fall
FOR the pharmaceutical companies with a turnover of less than Rs. 250 crore, time is ticking away fast to implement the Revised Schedule M. According to reports, a large number of MSME units, especially small and micro units with less than Rs. 50 crore turnover, is literally struggling to find the wherewithal to implement the Revised Schedule M which was brought by the Union Health Ministry to give the badly needed quality boost to the Indian pharmaceutical products.
2 min |
January 1, 2026
Chronicle Pharmabiz
Industry's digital transformation fuels emergence of high-demand careers
INDIAN pharma is in the midst of a digital transformation, as artificial intelligence, data analytics and automation take centrestage.
2 min |
January 1, 2026
Chronicle Pharmabiz
Corona expands production capacity at Bhayla facility
CORONA Remedies Limited, pharmaceutical formulation company, announced the successful commencement of capacity expansion for commercial production of tablets and capsules at its Bhayla manufacturing facility, effective from December 22, 2025.
1 min |
January 1, 2026
Chronicle Pharmabiz
Panel calls for penal provisions against misleading ads in Ayush
THE Parliamentary Panel on Health and Family Welfare has called for incorporation of strict penal provisions into the regulations to deter false and misleading advertisements and claims regarding the Ayush medicines and treatments.
2 min |
January 1, 2026
Chronicle Pharmabiz
India gains ground in excipients globally: Expert
INDIA is gaining ground as a reliable excipient supplier globally as Indian manufacturers are adding capacity and improving regulatory compliance.
2 min |
January 1, 2026
Chronicle Pharmabiz
PCI to introduce AI & MU modules in new syllabus
THE Pharmacy Council of India (PCI) is coming out with new curriculum which is inclusive of modules on integration of artificial intelligence (AI) and machine learning (ML) in formulation development strategies, molecular modelling, drug safety and other areas.
1 min |
January 1, 2026
Chronicle Pharmabiz
US FDA fortifies alliance with Telangana DCA
A high-level delegation from the US FDA concluded a significant meeting with the DCA in Telangana, two days ago, at the DCA office in Hyderabad.
2 min |
December 11, 2025
Chronicle Pharmabiz
India exploring possibilities to expand WHO standards for Indian medicines
INDIA is looking at possibilities to expand the World Health Organisation (WHO) global benchmarking standards for medicines, in order to unify and strengthen the drug regulatory mechanism for safety, quality and efficacy of medicines sold in the country.
1 min |
December 11, 2025
Chronicle Pharmabiz
Eli Lilly gets US FDA approval for Jaypirca
Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor.
1 min |
December 11, 2025
Chronicle Pharmabiz
Haryana DCA focuses on quality overhaul
THE Haryana drug control administration (DCA) is undertaking a major organizational overhaul focused on quality system upgrades and regulatory capacity building, particularly in response to the revised Schedule M norms.
2 min |
December 11, 2025
Chronicle Pharmabiz
DoC seeks inputs on trade issues faced with Japan
THE Department of Commerce (DoC), under the Union Commerce Ministry, has sought inputs from the industry on specific issues being faced in pharma trade with Japan.
1 min |
December 11, 2025
Chronicle Pharmabiz
AIOCD asks traders to strictly comply with ban on 35 FDCs
THE All India Organisation of Chemists and Druggists (AIOCD) has issued an urgent internal circular to all its state and Union territory trade bodies, demanding immediate and strict compliance with the ban on 35 fixed dose combinations (FDCs).
3 min |
December 11, 2025
Chronicle Pharmabiz
US FDA approves Bristol Myers Squibb's Breyanzi
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has granted approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.
2 min |
December 11, 2025
Chronicle Pharmabiz
CN Water presents AQU@Sense MB
CN Water is now combining core water-system expertise with digital assurance has launched AQU@Sense which delivers microbial test results in under 30 minutes, replacing traditional 5 to 7 days culture based methods.
1 min |
December 11, 2025
Chronicle Pharmabiz
Pharma logistics sees policy push as key catalyst for growth
INDIAN pharma's logistics sector is getting major boost from emerging policy support.
2 min |
December 11, 2025
Chronicle Pharmabiz
Lack of financial aid, expertise mar MSME prospects to meet revised Sch M deadline
INDUSTRY experts have raised alarm that lack of financial assistance and guidance on technical expertise have marred pharma MSMEs’ prospects to comply with revised Schedule M guidelines of December 31, 2025.
2 min |
December 11, 2025
Chronicle Pharmabiz
Import of bulk drugs, intermediates declines over 11% in October
IMPORTS of bulk drugs and intermediates to India registered a decline of 11.14% in the month of October, 2025, while the quantity of imports grew 20.74% during the month as compared to the same period of previous year.
2 min |
December 11, 2025
Chronicle Pharmabiz
Indian pharma ramps up global alignment
INDIAN pharma is accelerating its push toward global regulatory harmonization as authorities intensify efforts to align domestic standards with stringent International Council for Harmonisation (ICH) and World Health Organization (WHO) norms.
1 min |
December 11, 2025
Chronicle Pharmabiz
CDSCO announces risk classification of 119 medical devices
THE Central Drugs Standard Control Organisation (CDSCO) has announced risk classification of 119 medical devices pertaining to radiotherapy under the Medical Devices Rules (MDR), 2017, as part of updating classification of devices in order to keep regulating various medical devices under the rules.
2 min |
December 11, 2025
Chronicle Pharmabiz
Afghanistan initiates talks with Pharmexcil
A recent Afghan ministerial delegation to India has resulted in the initiation of focussed discussions with the Pharmaceuticals Export Promotion Council of India (Pharmexcil) towards strengthening bilateral cooperation in the pharma sector.
1 min |
December 11, 2025
Chronicle Pharmabiz
Growing Graph of IP
BOTSWANA has become the 18th country to recognize Indian Pharmacopoeia (IP) as a book of standard for medicines when it signed an MoU with the Indian government during Indian President Droupadi Murmu's recent visit to Botswana.
2 min |
December 11, 2025
Chronicle Pharmabiz
Innovent closes global collaboration with Takeda
INNOVENT Biologics, a leading biopharmaceutical company, announced that the global strategic collaboration with Takeda has closed and become effective following the satisfaction of all closing conditions.
1 min |
December 11, 2025
Chronicle Pharmabiz
AIOCD enforces mandatory 'MRP Minus 25%' rule for LBE claims
THE All India Organisation of Chemists and Druggists (AIOCD) has issued anew, internal mandatory circular demanding immediate and strict compliance from pharmaceutical stockists and companies regarding the settlement of loss before expiry (LBE) claims.
2 min |
December 11, 2025
Chronicle Pharmabiz
Ayurveda market booms in India even as US tariffs deliver a blow
INDIA'S Ayurveda sector is experiencing strong domestic momentum, driven by rising consumer preference for natural wellness products, expanded retail presence, and greater government support for Ayush initiatives.
2 min |
December 11, 2025
Chronicle Pharmabiz
IPC to come out with IP 2026 to strengthen standards of drugs
IN order to further strengthen the standards of drugs in India, the Indian Pharmacopoeia Commission (IPC) is coming out with the publication of 10th edition of the Indian Pharmacopoeia (IP 2026).
1 min |